Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $405
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko has maintained an Outperform rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $325 to $405.
March 20, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group analyst Liisa Bayko has reaffirmed an Outperform rating on Madrigal Pharmaceuticals and raised the price target from $325 to $405.
The increase in price target by a reputable analyst suggests a strong confidence in Madrigal Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100